Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | KAT8 | Q9H7Z6 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL941563 | 1.00 | BTK (0.64) | BTKKMT2AL3MBTL1EPHX1CA1 | |
| SCHEMBL15909157 | 1.00 | BTK (0.64) | BTKKMT2AL3MBTL1EPHX1CA1 | |
| SCHEMBL21027650 | 1.00 | BTK (0.64) | BTKKMT2AL3MBTL1EPHX1CA1 | |
| SCHEMBL941984 | 1.00 | BTK (0.64) | BTKKMT2AL3MBTL1EPHX1CA1 | |
| SCHEMBL25524123 | 1.00 | BTK (0.64) | BTKKMT2AL3MBTL1EPHX1CA1 | |
| SCHEMBL25319683 | 1.00 | BTK (0.64) | BTKKMT2AL3MBTL1EPHX1CA1 | |
| SCHEMBL14084772 | 0.97 | BTK (0.60) | BTKKMT2AL3MBTL1EPHX1CA1 | |
| SCHEMBL3906349 | 0.91 | BTK (0.55) | BTKKMT2AL3MBTL1EPHX1CA1 | |
| SCHEMBL19156343 | 0.91 | BTK (0.55) | BTKKMT2AL3MBTL1EPHX1CA1 | |
| SCHEMBL3903151 | 0.91 | BTK (0.55) | BTKKMT2AL3MBTL1EPHX1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062410-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12281111-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | ACLARIS THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20240228508-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2024-07-11 | — | — | US | disclosed |
| US-20240067643-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067643-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067643-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-11851442-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2023-12-26 | — | — | US | disclosed |
| US-11739086-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | ACLARIS THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739086-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | ACLARIS THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739086-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | ACLARIS THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-8012974-B2 | Pyrrolopyrazinyl urea kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-09-06 | — | — | US | disclosed |
| WO-2010063634-A1 | PYRROLOPYRAZINYL UREA KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-10 | — | — | WO | disclosed |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | ROCHE PALO ALTO LLC | 2010-06-10 | — | — | US | disclosed |
| US-7538233-B2 | Coumarins as iNOS inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2009-05-26 | — | — | US | disclosed |
| EP-1667988-A1 | COUMARINS AS INOS INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005026143-A1 | COUMARINS AS INOS INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050054681-A1 | Coumarins as iNOS inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-10 | — | — | US | disclosed |
| EP-0798298-B1 | THIAZOLIDINONE OR OXAZOLIDINONE DERIVATIVES TO TREAT ANGINA PECTORIS OR COMPOSITIONS CONTAINING THE SAME AS ACTIVE INGREDIENT | SANKYO CO (JP) | 2001-08-08 | — | — | EP | disclosed |
| US-5843973-A | Thiazolidinone compounds and composition for angina pectoris comprising the compounds as an active ingredient | SANKYO COMPANY, LIMITED (JP) | 1998-12-01 | — | — | US | disclosed |
| EP-0798298-A1 | THIAZOLIDINONE COMPOUNDS OR ANGINA PECTORIS REMEDY OR PREVENTIVE CONTAINING THE SAME AS ACTIVE INGREDIENT | SANKYO COMPANY LIMITED (JP) | 1997-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228508-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | BTK 11/4885KMT2A 1139/4885L3MBTL1 2113/4885 |
| US-12281111-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | JAK3, JAK1, JAK2 | BTK 237/4885KMT2A 1412/4885L3MBTL1 3761/4885 |
| US-11851442-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | JAK1, JAK3, JAK2 | BTK 11/4885KMT2A 1139/4885L3MBTL1 2113/4885 |
| US-20260062410-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | JAK3, JAK1, JAK2 | BTK 128/4885KMT2A 1863/4885L3MBTL1 4137/4885 |
| US-20240067643-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | JAK3, JAK1, JAK2 | BTK 237/4885KMT2A 1412/4885L3MBTL1 3761/4885 |
| US-11739086-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | JAK3, JAK1, JAK2 | BTK 237/4885KMT2A 1412/4885L3MBTL1 3761/4885 |
| US-20050054681-A1 | Coumarins as iNOS inhibitors | NOS2, NOS1, NOS3 | BTK 2116/4885KMT2A 4703/4885L3MBTL1 4864/4885 |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | JAK1, JAK3, ULK3 | BTK 67/4885KMT2A 1814/4885L3MBTL1 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.